Table 1.
Baseline demographic and clinical characteristics, N (%)
| All N = 118 |
FP group N = 34 |
Non FP group N = 84 |
FP vs non FP P value |
|
|---|---|---|---|---|
| Age at diagnosis (years) | 0.80 | |||
| Mean | 31 | 31 | 31 | |
| Range | 19–40 | 23–40 | 19–40 | |
| Male partner at the time of breast cancer diagnosis | 0.06 | |||
| Yes | 89 (75) | 30 (88) | 59 (70) | |
| No | 29 (25) | 4 (12) | 25 (30) | |
| Children at the time of breast cancer diagnosis | 0.03 | |||
| No | 82 (69) | 29 (85) | 53 (63) | |
| Yes | 36 (31) | 5 (15) | 31 (37) | |
| Infertility before cancer diagnosis | 0.28 | |||
| Yes | 9 (8) | 4 (12) | 5 (6) | |
| No | 109 (92) | 30 (88) | 79 (94) | |
| Germline mutation carrier | 0.86 | |||
| Positive test | 23 (19)a | 7 (21) | 16 (19) | |
| Negative test | 77 (65) | 21 (62) | 56 (67) | |
| No test | 18 (15) | 6 (18) | 12 (14) | |
| Tumor size (mm) | 0.04 | |||
| Median | 22 | 19 | 25 | |
| Range | 7–100 | 9–53 | 7–100 | |
| Lymph node status | 0.26 | |||
| N0/N0(i+) | 65 (55) | 23 (68) | 42 (50) | |
| N1mi/N1a | 37 (44) | 9 (26) | 28 (33) | |
| N2/N3 | 14 (12) | 2 (6) | 12 (14) | |
| Nx | 2 (2) | 0 (0) | 2 (2) | |
| Tumor grade | 0.52 | |||
| 1 | 9 (8) | 3 (9) | 6 (7) | |
| 2 | 31 (26) | 7 (21) | 24 (29) | |
| 3 | 75 (64) | 24 (71) | 51 (61) | |
| Unknown | 3 (3) | 0 (0) | 3 (4) | |
| Histology | 0.18 | |||
| Ductal | 110 (93) | 34 (100) | 76 (90) | |
| Lobular | 4 (3) | 0 (0) | 4 (5) | |
| Medullar | 4 (3) | 0 (0) | 4 (5) | |
| Hormone receptor status | 0.07 | |||
| Positive | 63 (53) | 23 (68) | 40 (48) | |
| Negative | 55 (47) | 11 (32) | 44 (52) | |
| HER2 status | 0.48 | |||
| Positive | 29 (25) | 10 (29) | 19 (23) | |
| Negative | 89 (75) | 24 (71) | 65 (77) | |
| Local therapy | 0.54 | |||
| Breast conserving | 34 (29) | 10 (38) | 34 (40) | |
| Unilateral mastectomy | 39 (33) | 14 (41) | 25 (30) | |
| Bilateral mastectomy | 34 (29) | 10 (29) | 24 (29) | |
| Unknown | 1 (1) | 0 (0) | 1 (1) | |
| Chemotherapyb | 0.04 | |||
| Second generation | 9 (8) | 2 (6) | 7 (8) | |
| Third generation | 108 (92) | 32 (94) | 76 (90) | |
| Other | 1 (1) | 0 (0) | 1 (1) | |
| HER2-targeted therapy | 0.48 | |||
| Yes | 29 (25) | 10 (29) | 19 (23) | |
| No | 89 (75) | 24 (71) | 65 (77) | |
| Endocrine therapy | 0.07 | |||
| Yes | 60 (51) | 22 (65) | 38 (45) | |
| Tamoxifen only | 11 (9) | 2 (6) | 9 (11) | |
| Tamoxifen + OFSc | 46 (39) | 19 (56) | 27 (32) | |
| Tamoxifen followed by aromatase inhibitor + OFS | 3 (3) | 1 (3) | 2 (2) | |
| No | 58 (49) | 12 (35) | 46 (55) | |
aBRCA1 gene mutation detected in 15 patients, BRCA2 gene mutation in 4 patients, CHECK2 mutation in 3 patients, PTEN mutation in 1 patient
bSecond-generation chemotherapy consisted of six 3-weekly cycles of FEC (5-fluorouracil, epirubicin, cyclophosphamide, 500, 100, and 500 mg/m2, respectively). Third-generation chemotherapy consisted of six 3-weekly cycles TAC (docetaxel, doxorubicin, and cyclophosphamide, 75, 50, and 500 mg/m2, respectively) or eight 3-weekly cycles AC-T (four cycles of doxorubicin and cyclophosphamide followed by four 3-weekly cycles of docetaxel or paclitaxel (AC-T; 60, 600, and 100 mg/m2 or 80 mg/2 weekly, respectively), whether or not in combination with trastuzumab (2 mg/kg). One other patient was treated with carboplatin (AUC2)/paclitaxel(80 mg/m2)/trastuzumab (2 mg/kg). So, all women received an alkylating-based regimen
cOFS, ovarian function suppression (chemotherapy-induced ovarian function failure or LhRHa or oophorectomy)